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Abstract
Introduction: After thyroidectomy and radioiodine therapy, patients with differentiated thyroid cancer (DTC) are indefinitely treated with 
levothyroxine (L-T4). Osteoporosis is a debated consequence of hypothyroxinaemia. The aim of this study was to evaluate bone mineral 
density (BMD) and fracture risk assessed by FRAX in a cohort of DTC women.
Material and methods. Seventy-four women with DTC (aged 56.5 ± 9.9 years) treated at the mean age of 51.9 ± 12.0 years were studied. 
Baseline BMD and FRAX were evaluated after 3.0 years (median). BMD and FRAX were further evaluated 5.5 years (median) after the 
baseline evaluation. A cohort of 120 euthyroid women, matched for age, BMI, and menopausal status, were evaluated as controls.
Results: L-T4 dosages were 813.6 ± 208.8 µg/week and 782.1 ± 184.4 µg/week at the baseline and second evaluation, respectively. The 
risks of major osteoporotic fracture (MOF) and hip fracture (HF) were similar in DTC patients and in controls. In DTC women, signifi-
cant changes in FRAX were found, with a higher increase in the probability of HF than of MOF. A similar change was found in controls. 
A significant inverse correlation (P < 0.001) between L-T4 dosage and HF/MOF probability on both first and second evaluations was 
found. A significant inverse correlation (P = 0.05) was found between fT4, TSH and duration of therapy and HF/MOF probability only 
on the second evaluation.
Conclusions: FRAX increase is a multi-factorial, age-related phenomenon. The absence of correlations between L-T4 dosage, length of 
therapy or fT4 levels and FRAX does not enable us to attribute an increased fracture risk to DTC women with well-controlled disease on 
therapy. (Endokrynol Pol 2016; 67 (4): 350–358)
Key words: bone fracture risk; osteoporosis; FRAX; thyroid cancer; levothyroxine therapy; hyperthyroxinaemia
Streszczenie
Wstęp: Chorzy ze zróżnicowanym rakiem tarczycy (DTC) po tyroidektomi i terapii jodem radioaktywnym muszą do końca życia przyjmo-
wać lewotyroksynę (L-T4). Jednym z możliwych następstw hypertyroksynemii jest osteoporoza. Badanie przeprowadzono w celu oceny 
gęstości mineralnej kości (BMD) oraz ryzyka złamania na podstawie wskaźnika FRAX w kohorcie kobiet chorych na DTC.
Materiał i metody: Badaniem objęto 74 kobiety z DTC (w wieku 56,5 ± 9,9 roku) poddane leczeniu w wieku 51,9 ± 12,0 lat. Wartości BMD 
i wskaźnika FRAX oceniono na początku badania oraz po upływie 3,0 lat (mediana). Następnie ponownie zbadano BMD i wskaźniki FRAX 
5,5 roku (mediana) po początkowej ocenie. Grupę kontrolną stanowiła kohorta 120 kobiet z prawidłową czynnością tarczycy dobranych 
pod względem wieku, wskaźnika BMI i występowania menopauzy.
Wyniki: Dawki L-T4 wynosiły 813,6 ± 208,8 µg/tydzień i 782,1 ± 184,4 µg/tydzień odpowiednio na początku badania i w trakcie drugiej 
oceny chorych. Ryzyko poważnego złamania osteoporotycznego (MOF) oraz złamania bliższego odcinka kości udowej (HF) było po-
dobne u chorych z DTC i w grupie kontrolnej. U kobiet z DTC stwierdzono istotne zmiany wartości wskaźnika FRAX, przy czym wzrost 
wskaźnika był większy w przypadku prawdopodobieństwa HF niż u osób zagrożonych MOF. Podobne zmiany stwierdzono w grupie 
kontrolnej. Zaobserwowano istotną odwrotną korelację (p < 0,001) między dawką L-T4 a prawdopodobieństwem HF/MOF zarówno 
przy pierwszej, jak i drugiej ocenie chorych. Natomiast istotną odwrotną korelację (p = 0,05) między dawką fT4, stężeniem TSH i czasem 
trwania terapii a prawdopodobieństwem HF/MOF stwierdzono tylko w czasie drugiej wizyty.
Wnioski: Zwiększenie wartości wskaźnika FRAX jest związane z wiekiem i zależy od wielu czynników. Brak korelacji między dawką 
L-T4, czasem trwania terapii lub stężeniem fT4 a wartością wskaźnika FRAX wskazuje, że nie należy przypisywać zwiększonego ryzyka 
złamań pacjentkom z DTC, u których uzyskano dobre wyrównanie choroby za pomocą terapii. (Endokrynol Pol 2016; 67 (4): 350–358)
Słowa kluczowe: ryzyko złamania kości; osteoporoza; FRAX; rak tarczycy; leczenie lewotyroksyną; hipertyroksynemia
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Introduction
Differentiated thyroid cancer (DTC) is an increasingly 
prevalent malignancy [1]. After thyroidectomy and 
postoperative radioiodine (RAI) therapy when neces-
sary, patients are indefinitely treated with levothyroxine 
(L-T4) to suppress thyrotropin (TSH) because inhibit-
ing this stimulating hormone is effective in reducing 
tumour recurrence rates [2]. The generally favourable 
prognosis of DTC allows patients to live a long life in 
a condition of exogenous subclinical hyperthyroxinae-
mia [1, 3].
Osteoporosis is a debated consequence of hyper-
thyroxinaemia, and the effect of thyroid function on 
fracture risk (FR) is not clear [4]. Indeed, although 
biologically active TSH-receptors have been found in 
human osteoblasts [5], the role of thyroid hormones 
in the pathogenesis of osteoporosis remains uncer-
tain6. While L-T4 is not associated with an increased 
FR or osteoporosis in either males or pre-menopausal 
women [4, 7], findings in post-menopausal women are 
controversial [4].
There is, however, no consensus regarding the im-
portance of various prognostic tools for risk assessment. 
Bone mineral density (BMD) is one of the main factors 
predictive of fractures, but a number of independent 
risk factors may provide additional information on the 
10-year FR (10-YFR) [8]. The WHO Collaborating Centre 
for Metabolic Bone Disease has recently ascertained 
that the 10-YFR can be estimated by means of the FR 
assessment tool (FRAX) score, which also includes clini-
cal data and BMD measured by means of dual-energy 
X-ray absorptiometry (DXA) [8].
The aim of this controlled study was to evaluate 
BMD and FRAX in a cohort of DTC women. Two assess-
ments were made in order to study changes in BMD and 
FRAX over time in relation to hormonal data, therapy, 
and disease evolution.
Material and methods
Subjects
We evaluated 74 DTC women (stage 1–4, baseline age 
56.5 ± 9.9 years, median 56 years; range 40–80 years) 
treated at the mean age of 51.9 ± 12.0 years. Among all 
DTC patients followed up in our Endocrine Unit, we 
select only female DTC subject with two or more bone 
densitometry examinations. Except for four Hispanic 
and two Asian women, all were Italian. In 95% of sub-
jects, the initial therapy consisted of thyroidectomy; 
this was followed by one or more cycles of RAI in 73%. 
Histology was papillary thyroid carcinoma (PTC), fol-
licular variant of PTC, and follicular thyroid carcinoma 
in 63, 10, and 1 subject/s, respectively. All DTC subjects 
were on L-T4 at the time of the study. L-T4 was started 
78 months (median; range 12–229 months) before 
thyroidectomy for goitre in 11% of patients. Before 
thyroidectomy, none of them had been treated with 
high L-T4 dosage (Table I).
A cohort of 120 euthyroid women, of similar age 
(baseline age 58.6 ± 9.9 years, median 57 years, range 
40–80 years), post-menopausal status, body mass index 
(BMI), and risk factors was evaluated as a control group 
(Table I). These patients were selected among all pa-
tients referred to the Rheumatology Clinic to undergo 
MOC DXA. Twenty-four women with Hashimoto’s 
disease were on L-T4 substitutive therapy on baseline 
evaluation. Another two women began L-T4 between 
the first and the second evaluations.
Study design
Clinical examination comprised history, evaluation 
of current therapies, physical examination, and neck 
ultrasonography (NUS). Baseline BMD and FRAX, 
calculated on femoral neck BMD, were evaluated 3.0 
years (median) after DTC diagnosis. BMD and FRAX 
evaluations were repeated after 5.0 years (median). 
Data on thyroid hormones, parathyroid hormone 
(PTH), serum calcium (S-Ca), and 25hydroxy-vitaminD 
(25OH-D) were available in all subjects. Thyroglobulin 
(Tg) and anti-Tg-antibodies (TgAb) were evaluable in 
all DTC patients.
Laboratory evaluations
Serum TSH, free-triiodothyronine, and free-thyroxine 
(fT4) were routinely measured by means of chemilumi-
nescence immunoassay (RocheDiagnostics, Mannheim, 
Germany). Thyroglobulin was assayed by means of sen-
sitive (until 2013; functional sensitivity 0.5 µg/L) and ul-
tra-sensitive (functional sensitivity 0.1 µg/L) chemilumi-
nescence immunoassay (Roche Diagnostics). In healthy 
subjects without goitre, normal Tg is 1.5~78.0 µg/L. 
Thyroglobulin Ab were evaluated by means of the 
DiaSorin assay (Saluggia, Italy); a TgAb < 100 mU/L 
was regarded as negative. PTH was analysed by means 
of two chemiluminescence immunoassays (Immuno-
lite2000, Diagnostic Products, San Juan Capistrano, CA, 
USA until 2010; subsequently, LIAISON N-tact PTH, 
DIASorin, Saluggia, Italy). Reproducibility of the data 
yielded by the two methods was excellent. Serum-Ca 
was determined by means of fully automatic equip-
ment (ModularP800, Roche Diagnostics). Evaluation 
of 25OH-D was performed by means of a chemilumi-
nescence method (LIAISON, DIASorin).
Imaging
Neck ultrasound (AU5 Idea and MyLabFive; Esaote, 
Genoa, Italy) was performed by means of a device 
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equipped with a linear 7.5–10 MHz linear transducer 
of 60 mm probe length. BMD in the lumbar spine and 
hip was measured by means of DXA using Hologic 
(QDR1500/DQR4500, Bedford, MA) and Lunar Prodigy 
instruments. The precision of BMD measurements is 
guaranteed by Phantom measurement, a quality control 
tool for cross-calibration used before every examina-
tion by the same operator. The coefficient of variation 
(CV) was 0.5%. The least-significant change (LSC) was 
2% and 2.8% for lumbar and hip BMD, respectively. 
Conversion equations from Hologic to GE-Lunar sys-
tems were used9. Using BMD data from two different 
apparatus does not create a bias; indeed, as the type of 
instrument can be specified, FRAX takes into account 
these possible differences, thereby rendering all data 
comparable. 
Survey measurements
FRAX has been used to calculate the 10-year probability 
(expressed as a percentage) of HF/MOF in subjects aged 
from 40 to 90 years. All FR factors included in FRAX (age, 
BMI, previous fracture, parental history of hip fracture, 
glucocorticoid therapy, smoking, alcohol intake, rheu-
matoid arthritis, and secondary causes of osteoporosis) 
were assessed, together with hip BMD data. FRAX was 
calculated on country-specific (Italy) data by means of 
a web version of computer-driven 3.8 software. 
Statistical analysis
The best index of DTC cure was taken to be an un-
detectable baseline or stimulated Tg with negative 
TgAb, together with a negative NUS at least one year 
after ablative therapy. Data were analysed by means 
of Prism 6.0 software (GraphPad Software, San Diego, 
CA, USA). All values quoted are mean ± SD or me-
dian (range), unless otherwise specified. Correlation 
analyses between variables were carried out by means 
of statistical nonparametric tests, while the Chi-square 
test was used to compare percentage data. Significance 
was taken as P < 0.05.
Results
Clinical data
We evaluated 194 women: 74 DTC patients and 120 eu-
thyroid controls. Adiposity was a more frequent finding 
in DTC subjects than in controls (P < 0.05), owing to 
the significantly greater number of DTC subjects with 
substantially stable BMI over 26 kg/m2 (DTC 44.6%, con-
trols 32%; P = 0.1). Statistically significant differences 
emerged only in data on supplemental calcium/vitamin 
D treatment. The L-T4 dosage in DTC patients did not 
change significantly over time (Table I). In patients with 
bone fractures, most fractures occurred at minor sites 
(ribs, wrist, foot); only one of the DTC patients had 
Table I. Principal epidemiological data, clinical data, and data on treatment effects in the study population (on 1st and 2nd 
evaluations). Data are expressed as mean ± SD or percentage unless otherwise specified, with medians in brackets. Significance 
was taken as P < 0.05
Tabela I. Najważniejsze dane epidemiologiczne, kliniczne i dotyczące efektów leczenia w badanej populacji (pierwsza 
i druga wizyta kontrolna). Dane przedstawiono jako średnie ± SD lub wartości procentowe z medianą w nawiasach, o ile nie 
zaznaczono inaczej. Wartości p < 0,05 przyjęto jako istotne statystycznie
Parameter DTC patients (n = 74) Controls (n = 120)
Baseline 2nd evaluation P valuea Baseline 2nd evaluation P valuea
BMI [kg/m2] 26.0 ± 5.3 26.1 ± 5.0 NS 24.5 ± 4.2 24.7 ± 4.2 NS
Weight [kg] 68.4 ± 15.7 (65.0) 66.1 ± 12.6 (64.0) NS 63.5 ± 10.9 (63.0) 63.8 ± 10.8 (63.0) NS
Menopausal state (%) 78 (n = 58) 85 (n = 63) NS 73.3 (n = 88) 79.2 (n = 95) NS
Smoking (%) 15 (n = 11) 16 (n = 12) NS 8 (n = 10) 7.5 (n = 9) NS
Disease-free for DTC recurrence (%) 99 (n = 73) 99 (n = 73) NS – – –
Subject with diseases involving bone (%)b 19 (n = 14) 22 (n = 16) NS 23.3 (n = 28) 23.3 (n = 28) NS
Calcium/vitamin D supplementation (%) 24 (n = 18) 62 (n = 46) P < 0.0001 25.8 (n = 31) 47.5 (n = 57) P < 0.0005
Anti-resorptive therapy (%) 22 (n = 16) 32 (n = 24) NS 20.8 (n = 25) 35 (n = 42) P < 0.01
Time on L-T4 (months) 70.9 ± 70.7 (48) 140.7 ± 115.8 (124) P < 0.0001 – – –
L-T4 dosages [µg/week] 813.6 ± 208.8  
(1.73 ± 0.42 µgxkg)
782.1 ± 184.4  
(1.78 ± 0.40 µgxkg)
P = 0.1 – – –
Cases of fracture (%) 7 (n = 5) 12 (n = 9) NS 4 (n = 5) 5 (n = 6) NS
aBaseline vs. follow-up; bprimary hyperparathyroidism, thyrotoxicosis, malabsorption, rheumatoid arthritis, and other autoimmune diseases; DTC — differentiated 
thyroid cancer; SD — standard deviation; BMI — body mass index; DTC — differentiated thyroid cancer; L-T4 — levohyroxine; NS — not significant
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a hip fracture at the first evaluation, while another suf-
fered a vertebral fracture between the first and second 
evaluations (Table I).
Laboratory data
As expected, TSH was significantly lower (P < 0.0001) 
and fT4 was higher (baseline P < 0.001; follow-up 
P < 0.01) in the L-T4-treated group than in controls at 
both evaluations. Adequate TSH concentrations under 
moderate hyperthyroxinaemia in DTC patients were 
more often observed on follow-up than on baseline 
evaluation. Serum Ca and 25OH-D showed no dif-
ferences between DTC patients and controls on both 
evaluations (Table II).
Serum PTH displayed differences between DTC 
patients and controls only at the follow-up examina-
tion (P < 0.01). Above-normal PTH was observed in 
17.6% of DTC patients and 9.2% of controls. However, 
primary hyperparathyroidism was diagnosed in only 
5 DTC patients and one control.
Table II shows the main biochemical and hormonal 
data and a comparison between baseline data and 
follow-up data within patients and controls separately.
Bone and FR evaluations
With regard to BMD, DXA results were significantly 
lower in DTC patients than in controls in the lumbar 
spine (P < 0.0001) and hip (P < 0.001). No significant 
changes in lumbar BMD (L2-L4) from baseline to 
follow-up evaluation were observed in either DTC 
patients or controls. However, a significant reduction 
in femoral neck BMD from baseline evaluation to 
follow-up was observed in controls, but not in DTC 
patients. The proportion of women in whom osteo-
paenia/osteoporosis criteria in the femoral neck were 
normal according to the T-score and WHO criteria 
did not significantly differ between DTC patients 
and controls (DTC: 69.6% at baseline and follow-up 
evaluations; controls: 67.5% and 61.7% at baseline and 
follow-up). In both groups, osteopaenia was slightly 
more frequent than osteoporosis, although the differ-
ence was not statistically significant. The MOF/HF risks 
measured by FRAX were similar in DTC patients and 
controls at both evaluations (Table II). The incidence of 
new cases of bone fracture was higher in DTC patients, 
although not significantly (Table I). Among six controls 
with bone fractures, HF was > 3% in four and MOF 
was > 20% in only one; among nine DTC patients 
with bone fractures, FRAX HF/MOF was > 3% and 
> 20% in four and two cases, respectively (Table II). In 
both of these subgroups, HF/MOF values were higher, 
both at the baseline and at follow-up evaluation, than 
those recorded in subjects without fractures, but were 
not significantly different between DTC and controls. 
Fractures occurred in 14% of controls and 35% of DTC 
with HF > 3%, and in 30% of controls and 75% of DTC 
with MOF > 20%. 
Finally, between the first and second evaluations, 
a percentage variation exceeding the value of LSC was 
found in 84% (N = 62) of DTC patients in lumbar BMD 
Table II. Principal hormonal, biochemical, and bone metabolism data in the study population (on 1st and 2nd evaluation). 
Data are expressed as mean ± SD unless otherwise specified or percentage, with medians in brackets. Significance was taken 
as P < 0.05
Tabela II. Najważniejsze dane hormonalne, biochemiczne i dotyczące metabolizmu kostnego w badanej populacji (pierwsza 
i druga wizyta kontrolna). Dane przedstawiono jako średnie ± SD lub jako wartości procentowe z medianą w nawiasach, 
o ile nie zaznaczono inaczej. Wartości p < 0,05 przyjęto jako istotne statystycznie
Parameter DTC patients (n = 74) Controls (n = 120)
Baseline 2nd evaluation P valuea Baseline 2nd evaluation P valuea
TSH [n.v. 0.3~4.2 mIU/L] 0.66 ± 1.22 (0.16) 0.23 ± 0.32 (0.07) P < 0.001 1.72 ± 1.91 (1.16) 1.91 ± 1.66 (1.4) NS
fT4 [n.v. 12.0~22.0 pmol/L] 20.50 ± 3.50 (20.7) 20.60 ± 3.30 (20.6) NS 18.20 ± 2.90 (18.4) 17.60 ± 5.00 (18.4) NS
S-Ca [n.v. 2.1~2.7 mmol/L] 2.40 ± 0.17 2.37 ± 0.12 NS 2.40 ± 0.15 2.40 ± 0.12 NS
25OHD [n.v. > 30 nmol/L] 31.60 ± 36.50 19.70 ± 11.80 NS 28.80 ± 25.60 24.90 ± 9.40 NS
BMD lumbar spine [g/cm2] 1.080 ± 0.199 (1.060) 1.051 ± 0.200 (1.014) NS 0.842 ± 0.145 (0.831) 0.835 ± 0.143 (0.809) NS
BMD hip [g/cm2] 0.792 ± 0.131 (0.781) 0.771 ± 0.111 (0.751) NS 0.981 ± 0.171 (0.982) 0.972 ± 0.173 (0.956) P < 0.05
FRAX HF (%) 1.2 ± 2.0 (0.6) 1.9 ± 3.2 (1.1) P < 0.0001 1.7 ± 2.5(0.8) 2.4 ± 3.7(1.1) P < 0.0001
FRAX MOF (%) 5.0 ± 4.1 (3.9) 6.8 ± 6.3 (5.3) P < 0.001 6.2 ± 4.8(4.7) 7.4 ± 5.3(5.4) P < 0.0001
FRAX HF (%) in fracture pts 3.5 ± 3.8 (1.9) 4.6 ± 3.9 (2.9) P < 0.05 5.3 ± 5.0 (4.5) 5.3 ± 3.7 (5.0) NS
FRAX MOF (%) in fracture pts 10.8 ± 6.8 (7.7) 13.9 ± 6.5 (12.0) P < 0.01 14.4 ± 8.2 (13.5) 15.7 ± 5.4 (16.0) NS
aBaseline vs. follow-up; DTC — differentiated thyroid cancer; SD — standard deviation; TSH — thyrotropin; fT4, free thyroxine; S-Ca — serum calcium; 25OHD — 
25-hydroxy-vitamin D; BMD — bone mineral density; FRAX — fracture risk assessment tool; HF — hip fracture; MOF — major osteoporotic fracture; n.v. — normal 
value; NS — not significant
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and 66% (N = 49) in hip BMD, and in 77% (N = 92) of 
controls in lumbar BMD and 63% (N = 75) in hip BMD.
Correlation analysis
The increase in TSH in DTC patients from baseline 
to follow-up was not related to significant changes 
in lumbar BMD. We did not find any correlation be-
tween hip and lumbar BMD and other factors of bone 
compromission (age, L-T4 dosage, BMI, etc.) in any of 
the subjects at either evaluation, with the exception of 
a positive correlation between hip BMD and weight 
(P < 0.0001). However, menopausal patients had lower 
values of lumbar and hip BMD than non-menopausal 
women (P < 0.05 in hip and 0.001 in lumbar BMD). 
The presence of other osteopaenia-inducing diseases 
did not determine differences in BMD.
A significant direct correlation emerged between 
the daily L-T4 dosage and hip and lumbar BMD (Fig. 1) 
and a significant inverse correlation emerged between 
L-T4 dosage and HF/MOF probability, at both evalua-
tions (Fig. 2). This correlation persisted on estimating 
the correlation of HF/MOF with LT-4 dose as µg/kg only 
at the follow-up evaluation. Moreover, the daily levels 
of L-T4 were not significantly correlated with age. No 
correlation was found between HF/MOF changes and 
the length of L-T4, fT4, or TSH. Only in DTC patients 
at baseline was a correlation found between S-Ca and 
HF/MOF probability (P < 0.05). 
A differentiated analysis of DTC patients on anti-
resorptive therapy (ART) in comparison with the re-
spective controls and with the naive patients (Tables 
III and IV) showed that hip BMD was lower in DTC 
patients, at both evaluations, whereas FRAX did not 
change; at both evaluations, hip BMD was lower in 
both DTC patients and controls on ART than in pa-
tients who were not on ART; consequently, FRAX was 
higher in patients on ART, who therefore had a higher 
FR. No significant change was observed between the 
first and second evaluation in any of the subgroups 
examined.
Figure 1. Significant correlation between L-T4 dosage and lumbar and hip BMD, both at the baseline (A, C) and on 2nd evaluation (B, D) 
in DTC patients
Rycina 1. Istotne korelacje między dawką L-T4 a BMD kręgów i bliższego odcinka kości udowej u chorych z DTC, na początku badania 
(A, C) oraz w czasie drugiej wizyty kontrolnej (B, D)
355
Endokrynologia Polska 2016; 67 (4)
PR
A
C
E 
O
RY
G
IN
A
LN
E
Figure 2. Significant inverse correlation between L-T4 dosage and HF/MOF probability evaluated by FRAX, both at the baseline (A, C) 
and on 2nd evaluation (B, D) in DTC patients
Rycina 2. Istotna odwrotna korelacja między dawką L-T4 a prawdopodobieństwem HF/MOF ocenionym na podstawie wskaźnika FRAX 
u chorych z DTC, na początku badania (A, C) oraz w czasie drugiej wizyty kontrolnej (B, D)
Table III. Principal bone metabolism data in the study population receiving anti-resorptive treatment (on 1st and 2nd evaluation). 
Data are expressed as mean ± SD, unless otherwise specified, or percentages
Tabela III. Najważniejsze dane dotyczące metabolizmu kostnego w badanej populacji stosującej leki antyresorpcyjne (pierwsza 
i druga wizyta kontrolna). Dane przedstawiono jako średnie ± SD lub jako wartości procentowe, o ile nie zaznaczono inaczej
Parameter DTC patients Controls
With anti-resorptive Without anti-resorptive With anti-resorptive Without anti-resorptive
Baseline  
(n = 13)
2nd evaluation 
(n = 22)
Baseline  
(n = 60)
2nd evaluation 
(n = 51)
Baseline  
(n = 25)
2nd evaluation 
(n = 42)
Baseline  
(n = 90)
2nd evaluation 
(n = 78)
BMD lumbar  
[g/cm2]
0.864 ± 0.126 0.945 ± 0.153 1.123 ± 0.183 1.097 ± 0.202171 0.905 ± 0.146 0.862 ± 0.147 0.826 ± 0.141 0.817 ± 0.138
BMD hip  
[g/cm2]
0.678 ± 0.123 0.721 ± 0.103 0.817 ± 0.120 0.792 ± 0.109 0.792 ± 0.095 0.831 ± 0.128 1.029 ± 0.152 1.046 ± 0.147
FRAX HF (%) 3.45 ± 3.66 4.05 ± 4.89 0.73 ± 0.97 0.70 ± 0.72 3.14 ± 2.96 3.93 ± 3.39 1.39 ± 2.24 1.61 ± 3.66
FRAX MOF (%) 9.91 ± 6.90 11.01 ± 8.85 3.98 ± 2.07 4.13 ± 2.09 8.58 ± 5.73 10.08 ± 6.43 5.58 ± 4.31 5.91 ± 3.84
DTC — differentiated thyroid cancer; SD — standard deviation; BMD — bone mineral density; FRAX — fracture risk assessment tool; HF — hip fracture; MOF — 
major osteoporotic fracture.
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Table IV. A differentiated analysis of DTC patients receiving anti-resorptive treatment in comparison with the respective 
controls, DTC patients without anti-resorptive treatment and controls without anti-resorptive treatment (on 1st and 2nd 
evaluation). Significance was taken as P < 0.05
Tabela IV. Analiza różnicowa chorych na DTC przyjmujących leki o działaniu antyresorpcyjnym w porównaniu z grupą 
kontrolną stosującą takie leczenie, chorymi na DTC niestosującymi leczenia antyresorpcyjnego i osobami z grupy kontrolnej 
niestosującymi leczenia antyresorpcyjnego (pierwsze i drugie badanie kontrolne). Wartości p < 0,05 przyjęto jako istotne 
statystycznie
Parameter DTC on ART 
vs. 
Controls on ART
Controls on ART 
vs. 
Controls without ART
DTC on ART 
vs. 
DTC without ART
Basal 2nd evaluation Basal 2nd evaluation Basal 2nd evaluation
BMD lumbar spine [g/cm2] NS P < 0.05 P < 0.05 NS P < 0.0001 P < 0.005
BMD hip [g/cm2] P < 0.005 P < 0.005 P < 0.0001 P < 0.0001 P < 0.0005 P < 0.05
FRAX HF (%) P = NS P = NS P < 0.0005 P < 0.0001 P < 0.001 P = NS
FRAX MOF (%) P = NS P = NS P < 0.005 P < 0.0001 P < 0.0005 P < 0.0001
DTC — differentiated thyroid cancer; ART — anti-resorptive therapy; BMD — bone mineral density; FRAX — fracture risk assessment tool; HF — hip fracture;  
MOF — major osteoporotic fracture; NS — not significant
Discussion
We compared the 10-YEAR in 74 DTC women in ex-
ogenous hyperthyroxinaemia and in 120 euthyroid 
women. DTC is a prevalent malignancy that mainly 
affects women [1], as does osteoporosis. We therefore 
selected an exclusively female sample. The distribution 
of histological diagnoses in DTC patients reflects that 
reported in the literature [10].
Vitamin D deficiency is common in Italy, particularly 
in the elderly. This finding is worse in those institution-
alised or with other comorbidities because of both low 
sun exposure and dietary imbalances, together with 
poor compliance with its therapeutic formulation [11]. 
The decrease in vitamin D at the second evaluation in 
all subjects, despite supplementation, can be explained 
by its age-related depletion in our patients, as in the 
general population.
The fractures recorded in both patient groups oc-
curred at the most common sites of osteoporotic fracture 
observed in the general population. Moreover, a sepa-
rate analysis of the patients with fractures confirmed 
the predictive capability of FRAX.
In our opinion, this study is particularly interesting 
because, although endogenous hyperthyroidism is 
a risk factor for secondary osteoporosis, the effects of 
supra-physiological L-T4 dosages on bone are still un-
der discussion [12]. Previous studies have not reported 
significant changes in BMD among premenopausal 
women and men [4, 7]. Findings in postmenopausal 
women have remained unclear4 and need further 
study. Moreover, there are no literature data on the 
FR evaluated by means of FRAX in postmenopausal 
women treated with L-T4 suppressive doses because 
of DTC [12].
Considerations on FR
Our data confirmed that, as reported in the literature 
[13], bone metabolism study and FR evaluation are im-
portant in patients on L-T4, when administered at high 
doses, as in DTC patients. Our data show that the HF 
risk is higher than the MOF risk and does not seem to 
be related to either the time on L-T4 or TSH. Conversely, 
in contrast with the data from some previous studies14, 
in our study, reducing the L-T4 dosage – in order to 
reduce the risk of disease recurrence and on account 
of increasing age – was associated with an increased 
FR, as evaluated by FRAX. While this increased risk 
seems to be age-related, we cannot exclude the pos-
sibility that other factors are involved. These include: 
1) lower compliance with ART; 2) disputed TSH ac-
tion on bone [15], in that its direct positive effect may 
decline; and 3) changes in age-related cytokine agents 
which remodel the skeletal characteristics of DTC 
patients [16]. Moreover, we cannot exclude the pos-
sibility that the L-T4 dosage at the first evaluation may 
be influenced by the manipulations necessary in the 
initial phases of therapy and staging (RAI, rhTSH-test).
Contrary to what would be expected in the state of 
pharmacologically induced hyperthyroxinaemia, obe-
sity is frequent in DTC patients [17], and our women 
were also overweight. It can therefore be hypothesised 
that the absence of significant deterioration in bone me-
tabolism may be the result of a protective effect against 
bone mass loss and that this effect is due to the very 
state of being overweight or to the slowing down of the 
metabolism [18]. Moreover, our data show that BMD is 
not influenced by other factors of bone compromission, 
except for weight and menopausal status.
The absence of a positive correlation between L-T4 
dosage, time on L-T4 or fT4 and FRAX does not allow 
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us to determine whether or not these patients have an 
increased FR. However, the data analysed showed that, 
in women on L-T4 for some time, the FR increases at 
the same rate as in healthy subjects, regardless of the 
difference detected on first evaluation. When there is 
a difference, this does not depend on the time of treat-
ment or reduction in the TSH levels.
Moreover, we can certainly say that the increase 
in FRAX score is a multifactorial phenomenon closely 
related to age; indeed, the study showed that BMD in 
women treated for DTC did not vary, unlike FRAX. 
This age-related increase in FRAX in the absence of 
a significant age-related reduction in BMD is to be 
expected, in that age is one of the main variables used 
to calculate FRAX. Although our data did not reveal 
a difference in the fracture probability and incidence 
of bone fracture between patients on L-T4 suppressive 
therapy and healthy subjects, it can be said that neither 
TSH reduction nor the duration of therapy results in 
an increase in long-term risk.
The negative correlation of L-T4 with the probability 
of fracture may be distorted, as the value of FRAX in-
creases with advancing age, while the need for L-T4 de-
creases as metabolic needs change. However, although 
FRAX is an age-related datum, as already mentioned, 
the daily L-T4 dosage in our study was not correlated 
with age, which confirms the significant correlation 
between FRAX and L-T4. This correlation is in line with 
the correlation seen between BMD and L-T4 dosage.
Finally, this study confirmed the importance of as-
sessing the 10-YFR by means of FRAX in these patients, 
as part of the follow-up recommended for their under-
lying disease [19].
Considerations on FRAX
FRAX is a valid means of estimating FR both in the 
general population and in patients with primary os-
teoporosis. Nevertheless, some considerations on the 
use of FRAX in DTC subjects should be made. Indeed, 
this algorithm is based on a finite number of variables, 
those considered most crucial in influencing FR [20]. 
However, it cannot consider all the factors involved 
in this process; indeed, hyperthyroidism itself [8] may 
be a risk factor, regardless of any other variable used 
to calculate the FRAX score. In this regard, it must be 
said that some new methods that include more factors, 
such as exercise and calcium intake (data not included 
in our study), are being studied. Moreover, studies 
on FRAX are constantly being updated and extended 
(e.g. Derived-FR-Assessment or DeFRA) [20], in order to make 
this instrument as accurate as possible so that it can be-
come a definitive approach to patients at risk of fracture.
Limitations
The first limitation of this study concerns the age of the 
patients. Between the first and the second evaluations 
the mean age rose from 56 to 61years; consequently, 
the percentage of menopausal patients increased 
(from 78% to 85%). This could be a confounding fac-
tor because the literature reports a strong protective 
effect of oestrogens on bone; thus, the impoverishing 
effect of thyroid hormone on bone [21] in pre-men-
opausal women may have been masked. However, 
to overcome this limitation, we selected a sample of 
age-matched controls. The second limitation concerns 
the presence of conditions and diseases affecting bone 
metabolism (Table II) in 20% of DTC patients, and of 
ART administration in 22% and 32% of patients at the 
first and second evaluations, respectively. However, 
our control group included the same percentage 
of patients on ART and with rheumatic diseases or 
diseases involving bone. Moreover, we performed 
a differentiated analysis of these patients in comparison 
with their respective controls and naive patients. The 
fact that patients on ART had a higher FR than naive 
patients can probably be ascribed to the fact that sub-
jects who require this therapy are those with lower 
BMD. Thus, proper application of the therapeutic 
indications enables the bias to be reduced. Finally, our 
median follow-up was only five years, while FRAX 
concerns a period of 10 years. A study conducted over 
a longer period of observation could therefore yield 
more significant data.
From a technological point of view, BMD was 
compared at the hip. Hyperthyroidism mainly affects 
cortical bone. Therefore, BMD at the radius is the most 
accurate measure of L-T4-related bone loss. However, 
wrist assessment was rarely performed in most pa-
tients. With regard to lumbar BMD, we measured the 
BMD of the L2-L4 segment. Extending this assessment 
to L1 tends to reduce the total BMD value, in that the 
BMD of L1 is lower than that of the L2-L4 segment. 
Moreover, the anatomical variability of L1 and its 
proximity to the lower ribs are factors that may alter 
the results. Radiography is a reliable means of evaluat-
ing asymptomatic vertebral fractures. However, it was 
not possible to carry out this exploration to confirm 
the results in all subjects. Indeed, as spinal X-ray was 
performed only in the event of painful symptoms, 
asymptomatic spinal fractures could have been missed.
Conclusions
FRAX increase seems to be an age-related multi-factorial 
phenomenon. The absence of positive correlations be-
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tween L-T4 dosage, length of therapy or fT4 and FRAX 
does not allow us to attribute an increased FR to DTC 
women with therapeutically well-controlled disease.
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